Ireland
--:--IST
Latest
Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact Astellas Expands Its 330 Million Euro Tralee Biopharma Facility with a Second Aseptic Filling Line to Double Drug-Product Capacity Xeolas Pharmaceuticals Opens 158,000 Sq Ft State-of-the-Art Baldoyle Facility to Scale Specialty Medicine Manufacturing Priya Life Science Partners with Fleming for the 9th Annual Corporate Compliance & Transparency in Life Sciences Summit in Zurich Ireland Has the Capital and the Lessons: Digital Project Management Is How They Become Delivery Dunbar Pharma Brings First Plant-Derived Dronabinol API to UK Market Through IPS Pharma Leveraging Priya Life Science as a Data Tracker: The Ultimate Use Case & Career Guide The €100K Reality Check: Why a Six-Figure Pharma Salary in Ireland Feels Different Than in Switzerland or Germany Ireland's €93.8 Billion Non-EU Pharma Export Engine: Trade Data, Destination Markets, and Economic Impact
Recruiting Not applicable

Evaluation of Serial Lung Ultrasound Data After Surfactant Treatments Applied With Different Methods in Preterm Babies

NCT06880016 · tracked via the Priya Life Science Turkey tracker
Phase
Not applicable
Started
2024-07-01
Last updated
2026-07-09

Condition(s) studied

Newborn ComplicationRespiratory Distress Syndrome, Newborn

Investigational drug(s) / intervention(s)

Evaluation of serial lung ultrasound data after ENSURE surfactant treatmentsEvaluation of serial lung ultrasound data after LISA surfactant treatments

Evaluation of serial lung ultrasound data after ENSURE surfactant treatments: Intubating the infant, administering intratracheal surfactant, and then extubating them back to nasal respiratory support (ENSURE method)

Evaluation of serial lung ultrasound data after LISA surfactant treatments: Delivering surfactant via a thin catheter (5F) directly into the trachea while the infant remains on existing nasal respiratory support, without disconnecting them from it (LISA method)

Study summary

This study aims to investigate the relationship between the method of surfactant administration and improvements in serial lung ultrasound findings in preterm infants requiring surfactant therapy.

Eligibility

Sex
ALL
Min age
1 Day
Max age
5 Days
Healthy volunteers
No
Inclusion Criteria: * Infants of families who agree to participate in the study * Preterm infants born before 32 weeks of gestation requiring surfactant therapy due to an RDS diagnosis. Exclusion Criteria: * Infants whose families did not provide consent * Infants with a syndromic appearance or congenital heart disease * Preterm infants born after 32 weeks of gestation

Primary outcome measure(s)

  • Evaluation of serial lung ultrasound data after surfactant treatments — 6 hours after completion of surfactant administration
    This study aims to investigate the relationship between the method of surfactant administration and improvements in serial lung ultrasound findings in preterm infants requiring surfactant therapy.

Trial sites (1)

FacilityCityRegionStatus
Melek Buyukeren Konya Karatay Recruiting
Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06880016 on ClinicalTrials.gov ↗ ← All trials in Turkey